Amundi Asset Management US’s NovoCure NVCR Stock Holding History

Amundi Asset Management US’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$5.38M	Buy	40,663 +9,435	+30%	+$1.49M	﹤0.01%	990
2020 Q4	$5.4M	Buy	+31,228	New	+$4.27M	﹤0.01%	956
2020 Q2	–	Sell	-11,400	Closed	-$768K	–	1664
2020 Q1	$768K	Buy	+11,400	New	+$901K	﹤0.01%	1130
2018 Q4	–	Sell	-2,066	Closed	-$108K	–	1648
2018 Q3	$108K	Hold	2,066	–	–	﹤0.01%	1513
2018 Q2	$65K	Hold	2,066	–	–	﹤0.01%	1493
2018 Q1	$45K	Hold	2,066	–	–	﹤0.01%	1491
2017 Q4	$42K	Buy	+2,066	New	+$39.8K	﹤0.01%	1509

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Amundi Asset Management US's NVCR Position: Q1 2021 in Review

Amundi Asset Management US increased its NovoCure (NVCR) stake by 30% in Q1 2021, buying an estimated $1.49M and bringing the position to 40,663 shares worth $5.38M. The position accounts for ﹤0.01% of the portfolio, ranked #990.

Amundi Asset Management US first reported a position in NVCR in Q4 2017 and has held it in 7 quarters since. The position peaked at $5.4M in Q4 2020. 328 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

Amundi Asset Management US held 40,663 shares of NovoCure worth $5.38M as of Q1 2021.
Amundi Asset Management US bought 9,435 NovoCure shares in Q1 2021, an estimated $1.49M.
NovoCure made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #990 holding.
Amundi Asset Management US first reported a position in NovoCure in Q4 2017 and has held it in 7 quarters since.
Amundi Asset Management US's NovoCure position peaked at $5.4M in Q4 2020.
328 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.